MIRA Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense
MIRA Pharmaceuticals, Inc. (MIRA) reported Increase (Decrease) in Prepaid Expense of $26.14 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $32.54K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$6.40K, a 106.16% decline year-over-year.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$33.79K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$40.47K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2025 was -$26.58K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2024 was -$189.07K, a 177.55% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. increase (decrease) in prepaid expense for fiscal 2023 was $243.80K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $26.14K 10-Q · filed 2026-08-12 | -$7.65K derived: sum of 3 quarters · filed 2026-08-12 | -$48.12K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$6.40K 10-Q · filed 2026-05-14 | -$40.19K derived: sum of 2 quarters · filed 2026-05-14 | -$80.65K derived: sum of 3 quarters · filed 2026-05-14 | -$136.86K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$33.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$74.26K derived: sum of 2 quarters · filed 2026-03-31 | -$130.47K derived: sum of 3 quarters · filed 2026-08-12 | -$26.58K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$40.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$96.68K derived: sum of 2 quarters · filed 2026-08-12 | $7.21K 10-Q · filed 2025-11-13 | -$24.64K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$56.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $47.67K 10-Q · filed 2026-08-12 | $15.83K derived: sum of 3 quarters · filed 2026-08-12 | -$6.22K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $103.88K 10-Q · filed 2026-05-14 | $72.04K derived: sum of 2 quarters · filed 2026-05-14 | $49.99K derived: sum of 3 quarters · filed 2026-05-14 | -$26.72K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$31.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$53.89K derived: sum of 2 quarters · filed 2026-03-31 | -$130.61K derived: sum of 3 quarters · filed 2026-03-31 | -$189.07K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$22.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$98.77K derived: sum of 2 quarters · filed 2025-11-13 | -$157.23K 10-Q · filed 2025-11-13 | -$116.25K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$76.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$135.18K 10-Q · filed 2025-08-14 | -$94.19K derived: sum of 3 quarters · filed 2025-08-14 | $66.10K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$58.47K 10-Q · filed 2025-05-14 | -$17.48K derived: sum of 2 quarters · filed 2025-05-14 | $142.81K derived: sum of 3 quarters · filed 2025-05-14 | $125.31K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $40.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $201.28K derived: sum of 2 quarters · filed 2025-03-28 | $183.77K derived: sum of 3 quarters · filed 2025-03-28 | $243.80K 10-K · filed 2025-03-28 |
| 2023-09-30 | $160.29K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-12 | $142.79K derived: sum of 2 quarters · filed 2024-11-12 | $202.82K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$17.51K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2024-08-16 | $42.52K 10-Q/A · filed 2024-08-16 | ||
| 2023-03-31 | $60.03K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $2.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $52.10K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $50.00K 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |